CY1110699T1 - Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο - Google Patents
Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοποInfo
- Publication number
- CY1110699T1 CY1110699T1 CY20101100054T CY101100054T CY1110699T1 CY 1110699 T1 CY1110699 T1 CY 1110699T1 CY 20101100054 T CY20101100054 T CY 20101100054T CY 101100054 T CY101100054 T CY 101100054T CY 1110699 T1 CY1110699 T1 CY 1110699T1
- Authority
- CY
- Cyprus
- Prior art keywords
- certification
- site
- capacity
- connection
- fields containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70528—CD58
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα εφεύρεση αφορά μέθοδο πιστοποίησης πεδίων θέσης σύνδεσης που διατηρούν την ικανότητα σύνδεσης προς έναν επίτοπο όταν τοποθετούνται C-τερματικά από τουλάχιστον ένα περαιτέρω πεδίο σε ένα ανασυνδυασμένο δισθενές ή πολυσθενές πολυπεπτίδιο. Η παρούσα εφεύρεση περαιτέρω αφορά ένα KIT που περιλαμβάνει συστατικά, όπως πάνελ ανασυνδυασμένων φορέων βακτηριακών συλλογών, που μορφομετατρέπονται με ένα πάνελ ανασυνδυασμένων φορέων, που είναι χρήσιμο στην διεξαγωγή της μεθόδου της εφεύρεσης. Περαιτέρω, περιγράφονται πεδία θέσης σύνδεσης, πρωτεΐνες σύντηξης που λαμβάνονται με την μέθοδο της εφεύρεσης, καθώς επίσης ομοιάζοντα με αντίσωμα μόρια που περιλαμβάνουν τέτοια πεδία και πρωτεΐνες. Περαιτέρω παρέχονται φαρμακευτικές και διαγνωστικές συνθέσεις που περιέχουν τις ανωτέρω περιγραφείσες πρωτεΐνες σύντηξης και πολυπεπτίδια.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97120096 | 1997-11-17 | ||
EP98963460A EP1032660B1 (en) | 1997-11-17 | 1998-11-16 | Method of identifying binding site domains that retain the capacity of binding to an epitop |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110699T1 true CY1110699T1 (el) | 2015-06-10 |
Family
ID=8227629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100054T CY1110699T1 (el) | 1997-11-17 | 2010-01-19 | Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο |
Country Status (13)
Country | Link |
---|---|
US (1) | US7435549B1 (el) |
EP (1) | EP1032660B1 (el) |
JP (2) | JP4327350B2 (el) |
AT (1) | ATE447613T1 (el) |
AU (1) | AU1873199A (el) |
CA (1) | CA2309679C (el) |
CY (1) | CY1110699T1 (el) |
DE (1) | DE69841273D1 (el) |
DK (1) | DK1032660T3 (el) |
ES (1) | ES2334184T3 (el) |
HK (1) | HK1031740A1 (el) |
PT (1) | PT1032660E (el) |
WO (1) | WO1999025818A1 (el) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420110B1 (en) * | 1998-10-19 | 2002-07-16 | Gpc Biotech, Inc. | Methods and reagents for isolating biologically active peptides |
GB9917027D0 (en) * | 1999-07-20 | 1999-09-22 | Affibody Technology Sweeden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
HUP0300919A2 (hu) * | 2000-03-24 | 2003-07-28 | Micromet Ag | Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel |
US20020137022A1 (en) * | 2000-08-02 | 2002-09-26 | Min Li | Methods and compositions for the construction and use of envelope viruses as display particles |
EP1629013B1 (en) * | 2003-05-31 | 2018-01-24 | Amgen Research (Munich) GmbH | Pharmaceutical composition comprising a bispecific antibody specific for epcam |
KR101229731B1 (ko) | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 cd3-바인더 |
CA2671264C (en) | 2006-11-30 | 2015-11-24 | Research Development Foundation | Improved immunoglobulin libraries |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
EP3620470B1 (en) | 2013-10-11 | 2023-07-26 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
US10160795B2 (en) | 2014-11-14 | 2018-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to Ebola virus glycoprotein and their use |
WO2016138160A1 (en) | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
EP3683233A1 (en) | 2015-03-20 | 2020-07-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to gp120 and their use |
WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
MY196869A (en) | 2016-06-27 | 2023-05-05 | Univ California | Cancer treatment combinations |
WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
EP3724223A1 (en) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2019165122A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
US20220089694A1 (en) | 2018-12-20 | 2022-03-24 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
US20220227853A1 (en) | 2019-05-03 | 2022-07-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
AU2020299382A1 (en) | 2019-07-02 | 2022-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind EGFRvIII and their use |
KR20230098334A (ko) | 2020-11-06 | 2023-07-03 | 암젠 리서치 (뮌헨) 게엠베하 | Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물 |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
EP4271709A1 (en) | 2020-12-31 | 2023-11-08 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
CN117396502A (zh) | 2021-02-09 | 2024-01-12 | 佐治亚大学研究基金会有限公司 | 针对肺炎球菌抗原的人类单克隆抗体 |
WO2022173670A1 (en) | 2021-02-09 | 2022-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
CA3232223A1 (en) | 2021-09-17 | 2023-03-23 | Ying Fu | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2024137381A1 (en) | 2022-12-19 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
WO2024138155A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP3672306B2 (ja) * | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5770356A (en) * | 1992-09-04 | 1998-06-23 | The Scripps Research Institute | Phagemids coexpressing a surface receptor and a surface heterologous protein |
ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
EP0699237B1 (en) | 1994-03-17 | 2003-02-19 | MERCK PATENT GmbH | Anti-egfr single-chain fvs and anti-egfr antibodies |
GB9500851D0 (en) * | 1995-01-17 | 1995-03-08 | Bionvent International Ab | Method of selecting specific bacteriophages |
EP0826696B1 (de) * | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
EP1005569A2 (en) * | 1997-08-01 | 2000-06-07 | MorphoSys AG | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
-
1998
- 1998-11-16 EP EP98963460A patent/EP1032660B1/en not_active Expired - Lifetime
- 1998-11-16 ES ES98963460T patent/ES2334184T3/es not_active Expired - Lifetime
- 1998-11-16 JP JP2000521184A patent/JP4327350B2/ja not_active Expired - Lifetime
- 1998-11-16 DK DK98963460.5T patent/DK1032660T3/da active
- 1998-11-16 AU AU18731/99A patent/AU1873199A/en not_active Abandoned
- 1998-11-16 PT PT98963460T patent/PT1032660E/pt unknown
- 1998-11-16 AT AT98963460T patent/ATE447613T1/de active
- 1998-11-16 CA CA2309679A patent/CA2309679C/en not_active Expired - Lifetime
- 1998-11-16 US US09/554,465 patent/US7435549B1/en not_active Expired - Fee Related
- 1998-11-16 WO PCT/EP1998/007313 patent/WO1999025818A1/en active Application Filing
- 1998-11-16 DE DE69841273T patent/DE69841273D1/de not_active Expired - Lifetime
-
2001
- 2001-02-23 HK HK01101344.0A patent/HK1031740A1/xx not_active IP Right Cessation
-
2009
- 2009-02-18 JP JP2009034882A patent/JP4977156B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-19 CY CY20101100054T patent/CY1110699T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE447613T1 (de) | 2009-11-15 |
JP4327350B2 (ja) | 2009-09-09 |
WO1999025818A1 (en) | 1999-05-27 |
CA2309679C (en) | 2010-07-20 |
CA2309679A1 (en) | 1999-05-27 |
PT1032660E (pt) | 2009-12-28 |
DE69841273D1 (de) | 2009-12-17 |
EP1032660B1 (en) | 2009-11-04 |
JP2009148280A (ja) | 2009-07-09 |
JP2002508924A (ja) | 2002-03-26 |
DK1032660T3 (da) | 2010-01-18 |
ES2334184T3 (es) | 2010-03-05 |
EP1032660A1 (en) | 2000-09-06 |
JP4977156B2 (ja) | 2012-07-18 |
US7435549B1 (en) | 2008-10-14 |
AU1873199A (en) | 1999-06-07 |
HK1031740A1 (en) | 2001-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110699T1 (el) | Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο | |
NO20000934D0 (no) | Adipocyttspesifikke proteinhomologer | |
WO2004065416A3 (en) | Synthetic antibody phage libraries | |
DE69930872D1 (de) | Antikörper gegen verkürzten vegf-d und deren verwendungen | |
ATE352618T1 (de) | Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält | |
AU4474497A (en) | Methods and means for selecting peptides and proteins having specific affinity for a target | |
DE69531302D1 (de) | Zellsystem mit einer spezifischen wechselwirkung von peptid-bindenden paaren | |
CA2124953A1 (en) | Peptides related to prion proteins | |
DE69309472D1 (de) | Fusionsproteine von monomeren und dimeren von antikörperfragmenten | |
WO1998047343A3 (en) | Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages | |
WO1995023859A3 (en) | Novel forms of t cells costimulatory molecules and uses therefor | |
ATE406439T1 (de) | Eukaryontische signalsequenzen für polypeptid- expressions- und polypeptid- präsentationsbibliotheken | |
DE69632827D1 (de) | Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen | |
DE69834643D1 (de) | Adipozyten-spezifische protein homologe | |
ATE372382T1 (de) | Ein faktor viii-polypeptid mit faktor viii:c- aktivität | |
DE69434384D1 (de) | Metalkomplexbildner | |
ATE172247T1 (de) | Car-rezeptoren und verwandte moleküle und entsprechende methoden | |
DE69333382D1 (de) | Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide | |
ATE360695T1 (de) | Cortistatin: neuropeptide, zusammensetzungen und methoden | |
EP2305710A3 (en) | Synthetic antibody phage libraries | |
WO1994026891A3 (en) | Purified mammalian flt3 ligands and agonists and antagonists thereof | |
WO2004094615A3 (en) | Prokaryotic collagen-like proteins and uses thereof | |
CA2218755A1 (en) | Monoclonal antibody to human beta 2 integrin alpha subunit | |
WO2000073446A3 (en) | Adipocyte complement related protein homolog zacrp6 | |
GB9929151D0 (en) | Peptide and polypeptide display |